Please Wait
Applying Filters...
menu
    • menu
    FDA approvals drop 8% in 2025, with fewer blockbusters; Brinsupri, Rhapsido make it to first-in-class list

    Data Compilation
    #PharmaFlow

    Pipeline Prospector Jan 2026 highlights: Astra, CSPC sign up to US$ 18.5 bn obesity deal; Wegovy’s pill version debuts in US

    Stock Recap
    #PipelineProspector

    Menu

    Rimiducid

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls download

    Filters

    clear-filterReset all filters
    ListList of Suppliers
    refreshReset Filter
    refresh Reset Filter
    Price Info Price Info
    product-page Product Main Page

    Log in to download the data

    Last Updated on PharmaCompass Virtual Booth Country Holder DMF No. Subject Submission Date Status Type GDUFA DMF Review GDUFA Review Date GDUFA Payment Date
    29/01/2026 Bellicum Pharmaceuticals
    U.S.A
    		 THE UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER 27424 AP1903 DRUG SUBSTANCE 2013-08-14 Active II N/A
    29/01/2026 Poseida Therapeutics, Inc
    U.S.A
    		 POSEIDA THERAPEUTICS 32053 RIMIDUCID DRUG SUBSTANCE AND RIMIDUCID FOR INJECTION 2018-04-30 Active II N/A
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.